2
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Glioblastoma
2
Spondylitis, Ankylosing
1
Signs and Symptoms
1
Psoriasis
1
Nutrition Disorders
1
Lymphoma
1
Leukemia, Myeloid, Acute
1
Insulin Resistance
1
Inflammatory Bowel Diseases
1
Glioma
1
Gastroparesis
1
Feeding and Eating Disorders
1
Esophageal Neoplasms
1
Epilepsy
1
Dumping Syndrome
1
Diarrhea
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Arthritis, Rheumatoid
1
Interventions
Adalimumab
19
Etanercept
16
Methotrexate
11
Infliximab
8
tocilizumab
7
Rituximab
7
golimumab
6
Abatacept
6
tofacitinib
5
Tumor Necrosis Factor Inhibitors
5
olokizumab
4
Certolizumab Pegol
4
Antirheumatic Agents
3
Saline Solution
2
RC-18
2
Nivolumab
2
Leflunomide
2
veltuzumab
1
upadacitinib
1
secukinumab
1
sarilumab
1
mavrilimumab
1
entecavir
1
cabozantinib
1
baricitinib
1
andecaliximab
1
Vitamin D
1
Vaccines
1
TACI receptor-IgG Fc fragment fusion protein
1
Syringes
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Arthritis, Rheumatoid
×
Sulfasalazine
×
Clear all
NCT03449758
2022-04-28
SariPRO
Sanofi
Phase 4
Completed
84 enrolled
36 charts